Ondansetron for the treatment of IBS with diarrhoea (IBS-D): Identifying the responder” - Ondansetron treatment in IBS-D

niversity of Nottingham0 个研究点目标入组 120 人开始时间: 2008年9月3日最近更新: 2019年2月28日

研究概览

暂无简介。

•IBS-D patients meeting the Rome III criteria.
•Male or female aged 18-75 years
•Women of child bearing potential (who have a negative pregnancy test) must agree to use methods of medically acceptable forms of contraception during the study., (e.g. implants, injectables, combined oral contraceptives, sexual abstinence or vasectomised partners)
•Patients who are able to give informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Women who are pregnant or breastfeeding,
•Patients that, in the opinion of the investigator, are considered unsuitable.
•Patients who have had abdominal surgery which may cause bowel symptoms similar to IBS (Please note, appendicectomy and cholecystectomy is not an exclusion)
•Patient unable to stop anti-diarrhoeal drugs
•Patients currently participating in another clinical trial or who have been in a trial in the previous three months
•Since many patients will be on SSRIs or tricyclics antidepressants these will not be an exclusion criteria, provided they have been on medication at least 3 months and that the dose remains unaltered throughout the study.

发起方

niversity of Nottingham